EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impacts of Mitochondrial Status After Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma Patients

Kotaro Sugawara iD, Shingo Sakashita iD, Takashi Fukuda, Chiaki Murakami, Daiji Oka, Gulanbar Amori, Yoshifumi Baba, Hiroaki Kanda, Noriko Motoi iD

Cancer Science · 2026

DOI: 10.1111/cas.70276 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Kotaro Sugawara und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Saitama Cancer Center, Saitama, Japan. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Mitochondria, Carcinoma, Squamous Cell. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Science Foundation, JSPS KAKENHI, Ichiro Kanehara Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prognostic significance of mitochondrial status after neoadjuvant chemotherapy (NAC) and its association with the tumor microenvironment (TME) in esophageal squamous cell carcinoma (ESCC) remains unclear. We analyzed 202 ESCC patients who underwent NAC followed by surgical resection. Mitochondrial status was quantified using an objective, immunohistochemistry‐based scoring system (Mito‐score). The optimal cut‐off value was determined by receiver operating characteristic curve analysis. Clinicopathological features, TME parameters (T‐cell density and programmed death ligand‐1 [PD‐L1] expression), and survival outcomes were compared between high and low Mito‐score groups. Multivariate Cox regression identified independent prognostic factors for overall survival (OS) and cancer‐specific survival (CSS). The high and low Mito‐score groups comprised 140 (69.3%) and 62 (30.7%) patients, respectively. NAC response rates and ypStages III–IV frequencies were similar in the two groups. PD‐L1 expression was significantly higher in high Mito‐score tumors ( p = 0.04), while T‐cell densities did not differ. High Mito‐score was associated with significantly worse OS (3‐year OS: 51.9% vs. 72.6%, p = 0.001) across both ypStages I–II ( p = 0.047) and ypStages III–IV ( p = 0.01) subgroups. In ypStages III–IV, high Mito‐score was also linked to poorer CSS ( p = 0.01). Multivariate analysis confirmed high Mito‐score to be an independent predictor of unfavorable OS and CSS. Overall, high Mito‐score after NAC identifies ESCC patients with significantly poorer survival, particularly among those with advanced pathological stages, thereby possibly serving as an independent prognostic biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaMitochondriaCarcinoma, Squamous CellHumansMaleFemaleNeoadjuvant TherapyMiddle AgedAgedTumor MicroenvironmentPrognosisB7-H1 AntigenAdultBiomarkers, TumorChemotherapy, AdjuvantNeoplasm Staging

Stichwörter der Autor:innen

esophageal squamous cell carcinomamitochondrianeoadjuvant chemotherapysurgerytumor microenvironment

Substanzen

B7-H1 AntigenCD274 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Saitama Cancer Center, Saitama, Japan.
  • Department of Gastroenterological Surgery, Saitama Cancer Center Hospital, Saitama, Japan.
  • Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Chiba, Japan.
  • Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
  • Center for Cancer Genomic Medicine, Saitama Cancer Center, Saitama, Japan.

ORCID-Profile: Kotaro Sugawara, Shingo Sakashita, Noriko Motoi

Förderung

  • Takeda Science Foundation
  • JSPS KAKENHI
  • Ichiro Kanehara Foundation
  • NEXT KAKENHI
  • AMED
  • Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care
  • Japan Agency for Medical Research and Development

Zitieren

APA

Sugawara, K., Sakashita, S., Fukuda, T., Murakami, C., Oka, D., Amori, G., Baba, Y., Kanda, H., & Motoi, N. (2026). Impacts of Mitochondrial Status After Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma Patients. Cancer Science. https://doi.org/10.1111/cas.70276

Vancouver

Sugawara K, Sakashita S, Fukuda T, Murakami C, Oka D, Amori G, et al. Impacts of Mitochondrial Status After Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma Patients. Cancer Science. 2026. doi:10.1111/cas.70276

BibTeX
@article{Sugawara2026,
  author = {Sugawara, Kotaro and Sakashita, Shingo and Fukuda, Takashi and Murakami, Chiaki and Oka, Daiji and Amori, Gulanbar and Baba, Yoshifumi and Kanda, Hiroaki and Motoi, Noriko},
  title = {Impacts of Mitochondrial Status After Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma Patients},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70276}
}
Kostenlos starten →